Stockscreener 앱 받기
0.9612
19.85%
0.1592
시간 외 거래:
1.00
0.0388
+4.04%
전일 마감가:
$0.802
열려 있는:
$0.8776
하루 거래량:
4.42M
Relative Volume:
2.36
시가총액:
$56.70M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-48.06
EPS:
-0.02
순현금흐름:
$-56.88M
1주 성능:
+35.78%
1개월 성능:
+110.97%
6개월 성능:
-3.20%
1년 성능:
-78.30%
1일 변동 폭
$0.8431
$1.00
1주일 범위
$0.625
$1.00
52주 변동 폭
$0.40
$4.94
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
명칭
Cytomx Therapeutics Inc
전화
650.515.3185
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
0.9612 | 56.70M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-14 | 재개 | Piper Sandler | Overweight |
| 2024-05-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2024-05-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-04-22 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-11-14 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-07-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-18 | 업그레이드 | Barclays | Underweight → Overweight |
| 2021-11-15 | 개시 | BTIG Research | Buy |
| 2021-05-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 개시 | JP Morgan | Overweight |
| 2021-03-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-24 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-11-11 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-05-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 개시 | Barclays | Overweight |
| 2018-11-26 | 개시 | Piper Jaffray | Overweight |
| 2018-10-15 | 개시 | Goldman | Neutral |
| 2018-09-13 | 개시 | H.C. Wainwright | Buy |
| 2018-06-01 | 개시 | SunTrust | Buy |
| 2018-01-05 | 개시 | Citigroup | Buy |
| 2017-09-08 | 개시 | Wedbush | Outperform |
| 2017-03-27 | 개시 | H.C. Wainwright | Buy |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-01-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 개시 | Oppenheimer | Outperform |
모두보기
Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 | CTMX Stock News - GuruFocus
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 - The Manila Times
Biotech Leader CytomX Sets Q1 2025 Earnings Date: Key Details for Investors - Stock Titan
CytomX Therapeutics Inc expected to post earnings of 12 cents a shareEarnings Preview - TradingView
CytomX Therapeutics Inc [CTMX] Stock sold by Insider McCarthy Sean A. for $22556.0 - knoxdaily.com
Get in on CytomX Therapeutics Inc’s (CTMX) buy-in window today! - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Observations on the CytomX Therapeutics Inc (NASDAQ:CTMX) Growth Curve - uspostnews.com
Market Update: CytomX Therapeutics Inc (CTMX) Sees Negative Movement, Closing at 0.71 - DWinneX
Renaissance Technologies LLC Grows Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
CytomX and Moderna unveil promising cancer therapy data By Investing.com - Investing.com Canada
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by JPMorgan Chase & Co. - Defense World
CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - ADVFN
Cytomx Therapeutics Presents Preclinical Data For mRNA Encoded Masked Il-12 Molecule In Collaboration With Moderna - marketscreener.com
CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting - The Manila Times
CytomX Unveils Breakthrough Cancer Treatment Data with Moderna at AACR | CTMX Stock News - Stock Titan
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $4.77 Consensus Price Target from Brokerages - Defense World
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect - MSN
Should investors be concerned about CytomX Therapeutics Inc (CTMX)? - uspostnews.com
CytomX Therapeutics Inc (CTMX)’s Market Momentum: Closing Strong at 0.73, Down -0.80 - DWinneX
CytomX Therapeutics Inc’s Shares Reel: -10.73% Quarterly Revenue Decline Amid 60.07M Market Cap - investchronicle.com
CytomX Therapeutics (NASDAQ:CTMX) Now Covered by Piper Sandler - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Coverage Initiated by Analysts at StockNews.com - Defense World
Piper Sandler sets CytomX stock target at $2.50, rates Overweight By Investing.com - Investing.com Nigeria
CytomX Therapeutics (CTMX) Stock Poised for Growth Amid Clinical - GuruFocus
Piper Sandler Reaffirms Their Buy Rating on CytomX Therapeutics (CTMX) - The Globe and Mail
Piper Sandler sets CytomX stock target at $2.50, rates Overweight - Investing.com
New Outlook On CytomX Therapeutics Inc - stocksregister.com
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Acquired by Prudential Financial Inc. - Defense World
CytomX Therapeutics Inc (NASDAQ: CTMX) 5.47% Incline Turns Investors Away - stocksregister.com
CTMX’s current quarter earnings: What analysts forecast? - uspostnews.com
Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive - simplywall.st
CytomX stock hits 52-week low at $0.56 amid market challenges By Investing.com - Investing.com South Africa
CytomX stock hits 52-week low at $0.56 amid market challenges - Investing.com
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Target Price at $5.02 - Defense World
Financial Metrics Check: CytomX Therapeutics Inc (CTMX)’s Ratios for Trailing Twelve Months - DWinneX
CytomX Therapeutics (NASDAQ:CTMX) Downgraded by StockNews.com to Hold - Defense World
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Virtu Financial LLC - Defense World
StockNews.com Downgrades CytomX Therapeutics (NASDAQ:CTMX) to Hold - The AM Reporter
CytomX Therapeutics Faces Critical Challenges in Product Development and Market Viability - MSN
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know - MSN
CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock - Investing.com India
CytomX therapeutics general counsel sells $6,111 in stock - Investing.com India
CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 By Investing.com - Investing.com Canada
Top Executives Cash Out: CytomX Therapeutics Stock Transactions Unveiled! - TipRanks
CytomX therapeutics CFO Christopher Ogden sells $5,122 in stock By Investing.com - Investing.com South Africa
CytomX Therapeutics CMO Yu-Waye Chu sells shares for $2,410 - Investing.com India
CytomX Therapeutics CEO sells $22,555 in stock By Investing.com - Investing.com South Africa
CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock - Investing.com India
CytomX Therapeutics SVP Marcia Belvin sells $11,687 in stock By Investing.com - Investing.com Canada
Cytomx Therapeutics Inc (CTMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):